<SEC-DOCUMENT>0001193125-22-112139.txt : 20220421
<SEC-HEADER>0001193125-22-112139.hdr.sgml : 20220421
<ACCEPTANCE-DATETIME>20220421080055
ACCESSION NUMBER:		0001193125-22-112139
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20220419
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220421
DATE AS OF CHANGE:		20220421

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sarepta Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000873303
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				930797222
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14895
		FILM NUMBER:		22839704

	BUSINESS ADDRESS:	
		STREET 1:		215 FIRST STREET
		STREET 2:		SUITE 415
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-274-4000

	MAIL ADDRESS:	
		STREET 1:		215 FIRST STREET
		STREET 2:		SUITE 415
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Sarepta Therapuetics, Inc.
		DATE OF NAME CHANGE:	20120712

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AVI BIOPHARMA INC
		DATE OF NAME CHANGE:	19980930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANTIVIRALS INC
		DATE OF NAME CHANGE:	19970123
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d329540d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srpt="http://www.sareptatherapeutics.com/20220419" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2022-04-19_to_2022-04-19">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2022-04-19_to_2022-04-19">0000873303</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="srpt-20220419.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-04-19_to_2022-04-19"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000873303</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-19</xbrli:startDate> <xbrli:endDate>2022-04-19</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-04-19_to_2022-04-19">8-K</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-04-19_to_2022-04-19" format="ixt:datemonthdayyearen">April 19, 2022</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2022-04-19_to_2022-04-19">Sarepta Therapeutics, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2022-04-19_to_2022-04-19" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2022-04-19_to_2022-04-19">001-14895</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2022-04-19_to_2022-04-19">93-0797222</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2022-04-19_to_2022-04-19">215 First Street</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2022-04-19_to_2022-04-19">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2022-04-19_to_2022-04-19" format="ixt-sec:stateprovnameen">Massachusetts</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2022-04-19_to_2022-04-19">02142</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2022-04-19_to_2022-04-19">(617)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2022-04-19_to_2022-04-19">274-4000</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-04-19_to_2022-04-19" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-04-19_to_2022-04-19" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-04-19_to_2022-04-19" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-04-19_to_2022-04-19" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-04-19_to_2022-04-19">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-04-19_to_2022-04-19">SRPT</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-04-19_to_2022-04-19" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-04-19_to_2022-04-19" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;19, 2022 (the &#8220;<span style="text-decoration:underline">Effective Date</span>&#8221;), Sarepta Therapeutics, Inc. (the &#8220;<span style="text-decoration:underline">Company</span>&#8221;) entered into a letter agreement (the &#8220;<span style="text-decoration:underline">2022</span> <span style="text-decoration:underline">Letter Agreement</span>&#8221;) with Douglas S. Ingram, the Company&#8217;s President and Chief Executive Officer, amending each of the following agreements between the Company and Mr.&#160;Ingram: (i)&#160;Performance Stock Option Award Agreement (the &#8220;<span style="text-decoration:underline">Stock Option Agreement</span>&#8221;), dated June&#160;26, 2017; (ii) Change in Control and Severance Agreement, effective June&#160;26, 2017, as amended by letter agreement dated June&#160;26, 2018 (the &#8220;<span style="text-decoration:underline">CIC Agreement</span>&#8221;); and (iii)&#160;Employment Agreement, dated as of June&#160;26, 2017, as amended by letter agreement dated June&#160;26, 2018 (the &#8220;<span style="text-decoration:underline">Employment Agreement</span>&#8221;). Although the vesting period under the Stock Option Agreement was set to end on June&#160;26, 2022 (the fifth anniversary of the date of the option grant), the Company determined that it was necessary, appropriate and in the best interests of the Company and its stockholders to enter into the 2022 Letter Agreement to provide certainty to investors and employees in advance of the expiration of Mr. Ingram&#8217;s contract, and to retain and incentivize him. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Amendment to Stock Option Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the compounded annual growth (&#8220;<span style="text-decoration:underline">CAGR</span>&#8221;) of the Company&#8217;s common stock and significant over-performance relative to the Nasdaq Biotech Index from the grant date of the option under the Stock Option Agreement to the Effective Date, the 2022 Letter Agreement amends the vesting schedule of the Stock Option Agreement to provide that 33.33% of the option will be vested on the Effective Date. In determining changes to the option, including the appropriate amount that should be vested on the Effective Date, 16.67% of the option would have vested in accordance with the original vesting schedule contained in the Stock Option Agreement as in effect prior to the Effective Date, based on the <span style="white-space:nowrap">20-day</span> trading average of the Company&#8217;s common stock immediately preceding the Effective Date (rather then immediately preceding June&#160;26, 2022, the fifth anniversary of the date of grant of the option). The remainder of the 33.33% of the option (<span style="font-style:italic">i.e</span>., an incremental 16.66%) was near the CAGR-adjusted vesting price for April 19, 2022 to meet the terms of the original agreement and is being accelerated in recognition of Mr.&#160;Ingram&#8217;s strong performance, extensive experience in the Company&#8217;s industry, overall compensation as compared to the compensation paid in the Company&#8217;s peer group and the competitive landscape for talent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The remaining unvested portion of the option shall vest in varying increments at any time between the Effective Date and June&#160;26, 2025 (the &#8220;<span style="text-decoration:underline">Measurement Period</span>&#8221;) if the Company&#8217;s common stock (based on the average of the closing price during any consecutive 20 trading day period during the Measurement Period) reaches any of the following levels: $105.74, $128.65, $155.37 and $186.36 (each a &#8220;<span style="text-decoration:underline">Company Target Stock Price</span>&#8221;), subject to Mr.&#160;Ingram&#8217;s continued service through each applicable vesting date <span style="font-style:italic"><span style="text-decoration:underline">and</span></span> the Company&#8217;s CAGR exceeds the CAGR of the Nasdaq Biotech Index in varying percentages (as set forth in the 2022 Letter Agreement) measured during the same period. The Company Target Stock Prices were calculated using the CAGR of the per share exercise price of the option from the date of grant until the fifth anniversary of the date of grant, using five percent increments starting with 25% CAGR and ending with 40% CAGR. The percentages of the option that will vest based on attainment of each Company Target Stock Price remain unchanged from the vesting percentages contained in the Stock Option Agreement as in effect immediately prior to the effective date of the 2022 Letter Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2022 Letter Agreement also adds a holding period with respect to any shares acquired pursuant to the exercise of any portion of the option. As of the Effective Date, Mr.&#160;Ingram will not be permitted during the Holding Period (as defined below) to sell or otherwise transfer or dispose of any of the shares acquired pursuant to the exercise of any portion of the option after deduction of any shares withheld or sold to pay the applicable aggregate exercise price and/or withholding taxes applicable to the exercise of the relevant portion of the option (other than certain transfers permitted for estate planning purposes where the transferee would be subject to the Holding Period). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Holding Period&#8221; is defined in the 2022 Letter Agreement as the one year period commencing on the exercise of any portion of the stock option, except that the Holding Period shall automatically end on the earliest to occur of the following: a Change in Control, Mr.&#160;Ingram&#8217;s death or disability, termination of Mr.&#160;Ingram by the Company without &#8220;Cause,&#8221; termination by Mr.&#160;Ingram with &#8220;Good Reason&#8221;, or Mr.&#160;Ingram&#8217;s termination following <span style="white-space:nowrap">non-renewal</span> by the Company and Mr.&#160;Ingram of the &#8220;Employment Term&#8221; as provided in Section&#160;2 of the Employment Agreement (and as each such term is defined in the Employment Agreement). </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expects to incur a significant <span style="white-space:nowrap">non-cash</span> accounting charge in connection with the 2022 Letter Agreement, which will be disclosed in the Company&#8217;s upcoming filings on Form <span style="white-space:nowrap">10-Q</span> in 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Amendment to Change in Control and Severance Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2022 Letter Agreement amends the CIC Agreement to provide that in the event of a &#8220;Covered Termination&#8221; during a &#8220;Change in Control Period&#8221; (each as defined in the CIC Agreement), any unvested portion of the option shall become vested with respect to that number of shares subject to the option that would have vested upon achievement of any of the Company Target Stock Price goals if the CAGR in the closing price of the Company&#8217;s common stock from the Effective Date to the date of the Change in Control (as defined in the CIC Agreement) (&#8220;<span style="text-decoration:underline">CIC CAGR Company</span>&#8221;) equals or exceeds the CAGR of the closing price of the Company&#8217;s common stock during the Measurement Period that would have been required to achieve the corresponding Company Stock Target Price on June&#160;26, 2025, subject to the vesting percentages set forth in the Stock Option Agreement and the extent to which the Company CIC CAGR (from the Effective Date to the date of the Change in Control) exceeds the Biotech Index CAGR (from the date of grant to the date of the Change in Control). However, no such vesting shall occur if the sale price of the Company&#8217;s common stock paid in a Change in Control (the &#8220;CIC Price&#8221;) occurring at any time during the <span style="white-space:nowrap">18-month</span> period commencing on the Effective Date does not equal at least $130 per share. If the CIC Price is less than $130 per share during such <span style="white-space:nowrap">18-month</span> period, the portion of the option that corresponds to the next applicable vesting column in the vesting table in the Stock Option Agreement (taking into account the extent to which the Company CIC CAGR exceeds the Biotech Index CAGR) shall vest on the Covered Termination during the Change in Control Period. Any portion of the option that does not vest under these provisions shall be immediately forfeited. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Amendment to Employment Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2022 Letter Agreement amends the Employment Agreement for consistency with the changes to the Stock Option Agreement described above and also provides that Mr.&#160;Ingram will become eligible for any future annual equity incentive awards after his first eight years of employment. In addition, outside of a Change of Control, in the event of a termination of Mr.&#160;Ingram by the Company without &#8220;Cause,&#8221; termination by Mr.&#160;Ingram with &#8220;Good Reason&#8221;, or Mr.&#160;Ingram&#8217;s termination following <span style="white-space:nowrap">non-renewal</span> by the Company, the option will continue to be eligible to vest for one year from the date of such termination, but in no event will vesting occur after June&#160;26, 2025. Any portion of the option that does not vest within such <span style="white-space:nowrap">one-year</span> period shall be forfeited. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary does not purport to be complete and is subject to, and qualified in its entirety by reference to, the complete copy of the 2022 Letter Agreement, which is filed as exhibit 10.1 to this Form <span style="white-space:nowrap">8-K.</span> Except as amended by the 2022 Letter Agreement, the Stock Option Agreement, CIC Agreement and Employment Agreement remain in effect in accordance with their terms. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"><span style="font-weight:bold">Exhibit<br />Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d329540dex101.htm">Letter Agreement, dated April&#160;19, 2022, between Sarepta Therapeutics, Inc. and Douglas S. Ingram </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The cover page from this Current Report on Form <span style="white-space:nowrap">8-K</span> of Sarepta Therapeutics, Inc., formatted in Inline XBRL and included as Exhibit&#160;101</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Sarepta Therapeutics, Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: April&#160;21, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ryan E. Brown</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Ryan E. Brown</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Senior Vice President, General Counsel</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d329540dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">April&nbsp;19, 2022 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Douglas&nbsp;S.
Ingram </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Sarepta Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">215 First Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02142 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Amendments to Performance Stock Option Award Agreement,</U></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B><U>Change in Control and Severance Agreement and Employment Agreement relating to Performance Stock Option</U></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Doug: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This letter agreement
(&#147;<U>Letter Agreement</U>&#148;) amends, effective on the date above, certain terms of the: (i)&nbsp;Performance Stock Option Award Agreement (the &#147;<U>Stock Option Agreement</U>&#148;), dated June&nbsp;26, 2017, between you and Sarepta
Therapeutics, Inc. (the &#147;<U>Company</U>&#148;) under the Company&#146;s 2014 Employment Commencement Incentive Plan, as amended; (ii)&nbsp;Change in Control and Severance Agreement, effective June&nbsp;26, 2017, between you and the Company, as
amended by letter agreement dated June&nbsp;26, 2018 (the &#147;<U>CIC Agreement</U>&#148;); and (iii)&nbsp;Employment Agreement, dated as of June&nbsp;26, 2017, between you and the Company, as amended by letter agreement dated June&nbsp;26, 2018
(the &#147;<U>Employment Agreement</U>&#148;). Capitalized terms used in Sections A, B and C below that are not otherwise defined in this Letter Agreement have the meanings set forth in the Stock Option Agreement, the CIC Agreement and the
Employment Agreement, respectively. Except as expressly provided herein, the Stock Option Agreement, the CIC Agreement and the Employment Agreement will continue in accordance with their respective terms and conditions. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Amendment to Performance Stock Option Award Agreement </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Vesting Schedule</U>. The section entitled &#147;Vesting Schedule&#148; beginning on page one of the Stock Option Agreement is hereby
deleted in its entirety (except for the last paragraph therein which shall be retained) and is hereby replaced with the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&#147;Vesting
Schedule</U>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective April&nbsp;19, 2022 (the &#147;<U>Effective Date</U>&#148;), subject to any acceleration
provisions contained in the Plan or set forth below, this Option may be exercised, in whole or in part, in accordance with the following schedule: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the CAGR of the Company&#146;s Common Stock and significant over-performance relative to the NASDAQ Biotech
Index (symbol NBI) from the Date of Grant to the Effective Date, on the Effective Date, 33.33% of this Option <I>(i.e.,</I> 1,099,890 shares of the Company&#146;s Common Stock underlying this Option) shall be vested (the &#147;<U>Vested
Tranche</U>&#148;). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The remaining unvested portion of this Option <I>(i.e.,</I> 66.67% of this
Option which corresponds to 2,200,110 shares of the Company&#146;s Common Stock underlying this Option) shall vest at any time between the Effective Date and June&nbsp;26, 2025 (the &#147;<U>Measurement Period</U>&#148;), upon achievement during the
Measurement Period of an average closing price for the Company&#146;s Common Stock set forth on the table below, calculated using the average of the closing prices of the Company&#146;s Common Stock during any consecutive 20 trading day period
occurring during the Measurement Period (the &#147;<U>Company Target Stock Price</U>&#148;), subject to the Participant&#146;s continued service to the Company or a subsidiary thereof from the Effective Date through each applicable date of
achievement of the Company Target Stock Price during the Measurement Period; provided, that during the period from the Date of Grant through the date of the achievement of the Company Target Stock Price, the compounded annual growth rate
(&#147;<U>CAGR</U>&#148;) of the Company&#146;s Common Stock Price (based on the average of the closing price during such consecutive 20 trading day period occurring during the Measurement Period) (the &#147;<U>Company CAGR</U>&#148;) exceeds the
CAGR of the NASDAQ Biotech Index (symbol NBI) (or any successor index) (the &#147;<U>Biotech Index</U>&#148;) (the &#147;<U>Biotech Index CAGR</U>&#148;) during the same period, as set forth in the table below and calculated at the time of vesting.
For the avoidance of doubt, the Company Target Stock Price will be measured on a rolling basis during the Measurement Period such that a new 20 consecutive trading day period will begin on every trading day, provided, however, that each of the 20
consecutive trading days must occur during the Measurement Period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Option shall be eligible for multiple vesting
events during the Measurement Period upon the achievement of higher levels of Company Target Stock Price set forth in table below. Once a Company Target Stock Price in the table below is first achieved, the applicable vesting percentage in the table
below that corresponds with the applicable percentage in the left column by which the Company CAGR exceeds the Biotech Index CAGR (i.e., Company CAGR less Biotech Index CAGR) (such applicable percentage, the &#147;<U>Relative CAGR
Percentage</U>&#148;) is multiplied by the total of number of shares of the Company&#146;s Common Stock underlying this Option. Upon achievement of the Company Target Stock Price during the Measurement Period in accordance with the table below, the
vesting percentage in the table below that corresponds to the applicable Relative CAGR Percentage shall apply to the Option, less the percentage of this Option that previously vested, except that the aggregate vesting shall not be less than the
vesting of the Vested Tranche. Once a portion of the Option vests based on achievement of a Company Target Stock Price under the table below, no further vesting at lower levels of Company Target Stock Price may occur. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Vesting Table </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">Company Target Stock Price (1):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">186.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">Percent Company CAGR exceeds Biotech Index CAGR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" NOWRAP ALIGN="center">Vesting Percentage</TD>
<TD VALIGN="bottom" NOWRAP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right"><FONT STYLE="white-space:nowrap">0.00%-0.99%</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.67</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33.33</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33.33</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right"><FONT STYLE="white-space:nowrap">1.00%-1.99%</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.33</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26.67</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43.33</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46.67</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right"><FONT STYLE="white-space:nowrap">2%-2.99%</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.67</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36.67</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53.33</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right"><FONT STYLE="white-space:nowrap">3%-3.99%</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46.67</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63.33</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73.33</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right"><FONT STYLE="white-space:nowrap">4%-4.99%</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33.33</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56.67</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73.33</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86.67</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">at least 5%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66.67</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83.33</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Company Target Stock Price dollar amounts set forth in the table above correspond to the Company CAGR
percentages as follows: $105.74 is based on 25% Company CAGR, $128.65 is based on 30% Company CAGR, $155.37 is based on 35% Company CAGR and $186.36 is based on 40% Company CAGR. These Company Target Stock Price dollar amounts were calculated using
the CAGR of the per share Exercise Price from the Date of Grant until the fifth anniversary of the Date of Grant. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as expressly provided herein, the unvested portion of the Option
(after taking into account the Vested Tranche) shall not vest prior to the achievement of the Company Target Stock Price during the Measurement Period with the corresponding Company CAGR exceeding the Biotech Index CAGR as set forth in the table
above. For the avoidance of doubt, no interpolation between stock price levels shall be used to determine the vesting percentage. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Participant acknowledges and agrees that this vesting schedule shall replace and supersede the vesting schedule set forth
in Section&nbsp;5(b) of the Employment Agreement dated June&nbsp;26, 2017, between you and the Company, as amended by letter agreement dated June&nbsp;26, 2018 (the &#147;<U>Employment Agreement</U>&#148;). In addition to being subject to the terms
and conditions in this Award Agreement and the Plan, the Option shall be subject to Section&nbsp;26 of the Employment Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.
<U>Holding Period</U>. The following new section entitled &#147;Holding Period&#148; is hereby added to the Stock Option Agreement after the section entitled &#147;Vesting Schedule.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Notwithstanding anything herein to the contrary, upon the vesting of any portion of this Option, the Participant shall
not be permitted during the Holding Period (as defined below) to sell or otherwise transfer or dispose of any of the shares of the Company&#146;s Common Stock acquired pursuant to the exercise of any portion of this Option after deduction of any
shares withheld or sold to pay the applicable aggregate exercise price and/or withholding taxes applicable to the exercise of the relevant portion of this Option (other than transfers for estate planning purposes to a Family Member, as defined under
Section&nbsp;2(t) of the Plan, provided, however, that such Family Member agrees to be subject to the Holding Period to the same extent it would have otherwise applied to the Participant). The term &#147;<U>Holding Period</U>&#148; means the <FONT
STYLE="white-space:nowrap">one-year</FONT> period commencing on the exercise of any portion of this Option, except that the Holding Period shall automatically end on the earliest to occur of the following: (i)&nbsp;a Change in Control: (ii)&nbsp;the
Participant&#146;s death; (ii)&nbsp;the Participant&#146;s Disability; or (iii)&nbsp;termination of the Participant by the Company without &#147;Cause,&#148; termination by the Participant with &#147;Good Reason&#148; or as a result of the
Participant&#146;s termination following <FONT STYLE="white-space:nowrap">non-renewal</FONT> by the Company and Participant of the &#147;Employment Term&#148; as provided in Section&nbsp;2 of the Employment Agreement (and as each such term is
defined in the Employment Agreement).&#148; </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Amendment to Change in Control and Severance Agreement </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Vesting of Performance Option Award.</U> Section&nbsp;3(c)(ii) of the CIC Agreement is hereby amended to read as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;ii. <U>Performance Option Award</U>. With respect to the Performance Option Award, any unvested portion of the
Performance Option Award shall automatically become vested and exercisable and any forfeiture restrictions or rights of repurchase thereon shall immediately lapse, in each case, with respect to that number of shares subject to the Performance Option
Award that would have vested upon achievement of any of the Company Target Stock Price goals if the compounded annual growth rate in the closing price of the Company&#146;s Common Stock from April&nbsp;19, 2022 to the date of the Change in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Control (&#147;<U>Company CIC CAGR</U>&#148;) equals or exceeds the compounded annual growth rate of the closing price of the Company&#146;s Common Stock from April&nbsp;19, 2022 to June&nbsp;26,
2025 (&#147;<U>Company Measurement Period CAGR</U>&#148;) that would have been required to achieve the corresponding Company Target Stock Price on June&nbsp;26, 2025, subject to the percentages set forth in the vesting table in the Performance
Option Award agreement and the extent to which the Company CIC CAGR exceeds the Biotech Index CAGR (in the case of the Company CIC CAGR, calculated from April&nbsp;19, 2022 to the date of the Change in Control and in the case of the Biotech Index
CAGR, from the Date of Grant to the date of the Change in Control) as set forth in the Performance Option Award agreement. Notwithstanding anything herein to the contrary, no such vesting and exercisability shall occur if the sale price of the
Company&#146;s common stock paid in the Change in Control (the &#147;<U>CIC Price</U>&#148;) occurring at any time during the eighteen (18)&nbsp;month period commencing on the Effective Date does not equal at least $130 per share. If the CIC Price
occurring at any time is less than $130 per share during such eighteen (18)&nbsp;month period, any unvested portion of the Performance Option Award shall automatically become vested and exercisable and any forfeiture restrictions or rights of
repurchase thereon shall immediately lapse, in each case, with respect to the number of shares subject to the Performance Option Award that correspond to the next applicable vesting percentage column under the vesting table set forth in the
Performance Option Award agreement (taking into account the extent to which the Company CIC CAGR exceeds the Biotech Index CAGR (in the case of the Company CIC Price CAGR, calculated from April&nbsp;19, 2022 to the date of the Change in Control and
in the case of the Biotech Index CAGR, from the Date of Grant to the date of the Change in Control) as set forth in the Performance Option Award agreement). Any portion of the Performance Option Award that does not vest pursuant to this
Section&nbsp;3(c)(ii) as of Executive&#146;s termination date shall be immediately forfeited and of no further force or effect. Exhibit A contains examples demonstrating the vesting under this Section&nbsp;3(c)(ii). The terms &#147;Company Target
Stock Price&#148; and &#147;Biotech Index CAGR&#148; (as modified herein) shall have the meanings set forth in the Performance Option Award.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Section&nbsp;3 (c)(iii) of the CIC Agreement is hereby deleted in its entirety. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>C.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Amendment to Employment Agreement </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Inducement Performance Option Award.</U> Section&nbsp;5(b) of the Employment Agreement is hereby amended to delete the entire section
other than the last sentence, which shall be retained in its entirety. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Annual Equity Awards.</U> Section&nbsp;5(c) of the
Employment Agreement is hereby amended by replacing the word &#147;fifth&#148; with the word &#147;eighth.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Employment
Termination due to <FONT STYLE="white-space:nowrap">Non-Renewal,</FONT> Without Cause or for Good Reason Outside of Change in Control Period.</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;8(c)(ii)(B) of the Employment Agreement is hereby amended in its entirety to read as follows:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Executive&#146;s Performance Option Award will remain outstanding and continue to vest in accordance with the terms of the Letter
Agreement dated April&nbsp;19, 2022 for a period of 1 year from the date of Executive&#146;s termination, provided, however, that in no event shall any continued vesting occur after June&nbsp;26, 2025. Any portion of the Performance Option Award
that does not vest within such <FONT STYLE="white-space:nowrap">1-year</FONT> period shall be forfeited and of no further force and effect.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Performance Option Award Vesting Examples.</U> The Employment Agreement is hereby amended to delete Exhibit A in its entirety. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>D.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Miscellaneous </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Entire Understanding</U>. This Letter Agreement sets forth the entire agreement between you and the Company regarding the amendments of
the Stock Option Agreement, CIC Agreement and Employment Agreement and supersedes any other discussions or agreements between you and the Company regarding the matters addressed herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Severability; Counterparts</U>. The invalidity or unenforceability of any provision of this Letter Agreement will not affect the
validity or enforceability of any other provision. If any provision of this Letter Agreement is held invalid or unenforceable in part, the remaining portion of such provision, together with all other provisions of this Letter Agreement, will remain
valid and enforceable and continue in full force and effect to the fullest extent consistent with law. This Letter Agreement may be executed in several counterparts (including, without limitation, by facsimile, PDF or electronic transmission), each
of which will be deemed an original, and such counterparts will constitute one and the same instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Remainder of Page
Intentionally Left Blank} </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To indicate your agreement with the foregoing, please sign and return this Letter Agreement
to me. This Letter Agreement will become effective as of the date on which you sign below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SAREPTA THERAPEUTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Claude Nicaise</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Claude Nicaise, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chair of the Compensation Committee of the Board of Directors</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Accepted and Agreed:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Douglas S. Ingram</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: Douglas S. Ingram</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: April&nbsp;19, 2022</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PERFORMANCE OPTION AWARD VESTING EXAMPLES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DOUBLE TRIGGER (CIC) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>In each of the
following examples, assume that the closing price of the Company&#146;s common stock on the Effective Date is $85 per share. Utilizing this assumption, the Company Target Stock Prices listed in the vesting table correspond to the following Company
CAGRs for the Measurement Period </B><B><I>(i.e.,</I></B><B> the Effective Date to June&nbsp;26, 2025) as follows: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Target Stock Company CAGR Price </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="60%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD WIDTH="35%"></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>$105.74</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><B>7.50%</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>$128.65</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><B>14.80%</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>$155.37</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><B>22.27%</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>$186.35</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><B>29.91%</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Example A: </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assume that a
Change in Control occurs on the one year anniversary of the Effective Date <I>(i.e., </I>April&nbsp;19, 2023) with a sale price paid in the Change in Control equal to $110 per share. In this case, the Company CIC CAGR equals 29.41%. Assume the
Company CIC CAGR (for the period beginning on the Effective Date and ending on the date of the Change in Control) exceeds the Biotech Index CAGR (for the period beginning on the Date of Grant and ending on the date of the Change in Control) by at
least 5%. Assume that none of the Company Target Stock Prices were achieved between the Effective Date and the Change in Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the vesting
table, the Option will vest under the column for a Company Target Stock Price of $128.65 with a Company CIC CAGR (for the period beginning on the Effective Date and ending on the date of the Change in Control) that exceeds the Biotech Index CAGR
(for the period beginning on the Date of Grant and ending on the date of the Change in Control) by at least 5%, resulting in a vesting percentage of 66.67% of the shares subject to the Option <I>(i.e.,</I> 2,200,110 shares), less the amount already
vested <I>(i.e.,</I> 33.33% or 1,099,890 shares). Accordingly, an additional 1,100,220 shares subject to the Option will vest upon a &#147;Covered Termination&#148; during a &#147;Change in Control Period&#148; under Section&nbsp;3 (c)(ii) of the
CIC Agreement (as amended pursuant to the Letter Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Example B: </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assume that a Change in Control occurs on the second year anniversary of the Effective Date <I>(i.e., </I>April&nbsp;19, 2024) with a sale price paid in the
Change in Control equal to $130 per share. In this case, the Company CIC CAGR equals 23.67%. Assume the Company CIC CAGR (for the period beginning on the Effective Date and ending on the date of the Change in Control) exceeds the Biotech Index CAGR
(for the period beginning on the Date of Grant and ending on the date of the Change in Control) by 4.5%. Assume that none of the Company Target Stock Prices were achieved between the Effective Date and the Change in Control. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Company Target Stock Price of $155.37 corresponds to a Company CAGR during the Measurement Period of
22.27%. Under the vesting table, the Option will vest under the column for a Company Target Stock Price of $155.37 with a Company CIC CAGR (for the period beginning on the Effective Date and ending on the date of the Change in Control) that exceeds
the Biotech Index CAGR (for the period beginning on the Date of Grant and ending on the date of the Change in Control) by 4.5%, resulting in a vesting percentage of 73.33% of the shares subject to the Option (<I>i.e.</I>, 2,419,890 shares), less the
amount already vested (<I>i.e.</I>, 33.33% or 1,099,890 shares). Accordingly, an additional 1,320,000 shares subject to the Option will vest upon a &#147;Covered Termination&#148; during a &#147;Change in Control Period&#148; under
Section&nbsp;3(c)(ii) of the CIC Agreement (as amended pursuant to the Letter Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If, however, the Company CIC CAGR exceeds the Biotech Index
CAGR (for the period beginning on the Date of Grant and ending on the date of the Change in Control) by at least 5%, the resulting vesting percentage would be 83.33% of the shares subject to the Option <I>(i.e.,</I> 2,749,890 shares), less the
amount already vested <I>(i.e.,</I> 33.33% or 1,099,890 shares). Accordingly, an additional 1,650,000 shares subject to the Option will vest upon a &#147;Covered Termination&#148; during a &#147;Change in Control Period&#148; under Section&nbsp;3
(c)(ii) of the CIC Agreement (as amended pursuant to the Letter Agreement). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>These examples are provided for illustration purposes only. Capitalized
terms used herein shall have the meaning set forth in the Letter Agreement. </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>srpt-20220419.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 4/21/2022 2:46:03 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2021-01-31"
  xmlns:srpt="http://www.sareptatherapeutics.com/20220419"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.sareptatherapeutics.com/20220419"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" namespace="http://xbrl.sec.gov/dei/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="srpt-20220419_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="srpt-20220419_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.sareptatherapeutics.com//20220419/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>srpt-20220419_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 4/21/2022 2:46:03 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>srpt-20220419_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 4/21/2022 2:46:03 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sareptatherapeutics.com//20220419/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="srpt-20220419.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.sareptatherapeutics.com//20220419/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139883031182088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Apr. 19, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000873303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 19,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Sarepta Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">93-0797222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">215 First Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">274-4000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SRPT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>d329540d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="srpt-20220419.xsd" xlink:type="simple"/>
    <context id="duration_2022-04-19_to_2022-04-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2022-04-19_to_2022-04-19">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2022-04-19_to_2022-04-19"
      id="Hidden_dei_EntityCentralIndexKey">0000873303</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2022-04-19_to_2022-04-19">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2022-04-19_to_2022-04-19">2022-04-19</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2022-04-19_to_2022-04-19">Sarepta Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2022-04-19_to_2022-04-19">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2022-04-19_to_2022-04-19">001-14895</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2022-04-19_to_2022-04-19">93-0797222</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2022-04-19_to_2022-04-19">215 First Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2022-04-19_to_2022-04-19">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2022-04-19_to_2022-04-19">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2022-04-19_to_2022-04-19">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2022-04-19_to_2022-04-19">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2022-04-19_to_2022-04-19">274-4000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2022-04-19_to_2022-04-19">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2022-04-19_to_2022-04-19">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2022-04-19_to_2022-04-19">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2022-04-19_to_2022-04-19">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2022-04-19_to_2022-04-19">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-04-19_to_2022-04-19">SRPT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-04-19_to_2022-04-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2022-04-19_to_2022-04-19">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ &D"55!PX9>H_ 0  / (
M  \   !X;"]W;W)K8F]O:RYX;6R-4<MNPD ,_)75?D 34(M41+B4/I"J%I6*
M^Y)UB,4^(J\#+5]?)U%4I%YZ\GILC6=F%^=(QWV,1_7E74B%KIF;>9:EL@9O
MTDUL(,BDBN0-2TN'+#4$QJ8:@+W+IGD^R[S!H)>+D6M#V743&4K&& 3L@!W"
M.?W.NU:=,.$>'?)WH?NW ZT\!O1X 5OH7*M4Q_-+)+S$P,9M2XK.%7HR#'9
MC.4?>-N)_#3[U"-L]A]&A!1ZE@MAA92XW^CYC6@\@2P/7<OQ"1T#K0S#,\6V
MP7#H:,1%=F6CSV&L0XAS^D^,L:JPA%4L6P^!AQP)7"<PI!J;I%4P'@H]KB@3
MK'H,+"&I=1BH9+=S*J?7=G#-(O<J0YJC#&AM!^&C6@L5!K!O<B )+LF5&U)=
MZ7FFMW>3>TFH=>Y!L/?P&HT=S8\?M_P!4$L#!!0    ( !I E50D'INBK0
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ &D"55,&":6KN    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M&D"55)E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    "  :0)54%D=ICC@$  !($   &
M    @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M&D"55)^@&_"Q @  X@P   T              ( !>PP  'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    "  :0)54EXJ[',     3 @  "P              @ %7
M#P  7W)E;',O+G)E;'-02P$"% ,4    "  :0)54'#AEZC\!   \ @  #P
M            @ % $   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ &D"5
M5"0>FZ*M    ^ $  !H              ( !K!$  'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ &D"55&60>9(9 0  SP,  !,
M         ( !D1(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^
) @  VQ,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d329540d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sareptatherapeutics.com//20220419/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d329540d8k.htm">d329540d8k.htm</File>
    <File>d329540dex101.htm</File>
    <File>srpt-20220419.xsd</File>
    <File>srpt-20220419_lab.xml</File>
    <File>srpt-20220419_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d329540d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d329540d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "srpt-20220419_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "srpt-20220419_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "srpt-20220419.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "srpt",
   "nsuri": "http://www.sareptatherapeutics.com/20220419",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d329540d8k.htm",
      "contextRef": "duration_2022-04-19_to_2022-04-19",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.sareptatherapeutics.com//20220419/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d329540d8k.htm",
      "contextRef": "duration_2022-04-19_to_2022-04-19",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sareptatherapeutics.com//20220419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sareptatherapeutics.com//20220419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sareptatherapeutics.com//20220419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sareptatherapeutics.com//20220419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sareptatherapeutics.com//20220419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sareptatherapeutics.com//20220419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sareptatherapeutics.com//20220419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sareptatherapeutics.com//20220419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sareptatherapeutics.com//20220419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sareptatherapeutics.com//20220419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sareptatherapeutics.com//20220419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sareptatherapeutics.com//20220419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sareptatherapeutics.com//20220419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sareptatherapeutics.com//20220419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sareptatherapeutics.com//20220419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sareptatherapeutics.com//20220419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sareptatherapeutics.com//20220419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sareptatherapeutics.com//20220419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sareptatherapeutics.com//20220419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sareptatherapeutics.com//20220419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sareptatherapeutics.com//20220419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sareptatherapeutics.com//20220419/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001193125-22-112139-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-112139-xbrl.zip
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MVGP[S+_W=IA_;P6L_GUL@?V7$@?-S>WFJY,%;TF]OAU0]]^.,#A8P11\JY;
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MHYY+ *#MC;%0RB4C$X2[QQ1PDG"7+Y^BQG\"$VLF9X'K!5H/!]5 HWC9DBJ
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MRNG.V?7Y'_#AQ>#K9>O_ 5!+ P04    "  :0)54/5637$<#  !T"P  $0
M '-R<'0M,C R,C T,3DN>'-DO5;?;],P$'Y'XG\X\@02B9MN0VJT#0%CTJ1M
MH#(0;\A-KJV%8P?;V=;_GK.3=&FWEK(A^E+7=]_==S_=P[>WI81K-%9H=12E
MR2 "5+DNA)H=1;6-N<V%B-X>/W]V^"*.X>3T[!)BF#M7V8RQFYN;I)@*9;6L
M'5FP2:Y+!G'<Z7^X^@K?&NL9C%$BMP@EMPX-O*^%+++A8#@<I.E!D@[[.(/<
M&X2".\Q@GPU3YC5AF.V_R09[\/D"/@8S"JY$B7VHKA9&S.8.7N:O((!.M%(H
M)2[@5"BN<L$E?.DHOX8SE2?P3DH8>Y@EGA;--19):_76%IG-YUCRY\\ *&'*
M9HI,UN51Y#/1)N)V8F2BS8P5SC"WJ)"14DQ::$0>]:!_QMW#4"6\Q"Z!4VXG
M =1)?'K2>)#&>VD/9TWE5IQ9;K!RW,W1\ HI WE3LU"&_734PQ8HEM# T6*>
MS/0U(T'PUM/U<O%P5,/!8(]1BSA*//8@4JB?6Q!>/*%NZ3NY![G9"X!T-!JQ
M(%VC5+C5"%KK!ZP1!FWNG!&3VN&I-N4)3GDM"56K7S678BJP"%K4NB4JMZ*S
MJN&XF:&[Y"7:BN?XV*Q3LST4(K%.V?>+\R^A#Z-C#P (K2G*2AL'38>>ZSP,
MSI;,^E]Q5Y#87\7ID-HF(6,1J <#V%!-8$\FTM7Y44263;(S$;NIF?TA]H=-
MWA\>@4=G8'W8??PC'W_Z9J?X[RV+?\!$J\NGDNEMO,?71'$:D*8JX;A[7>Z0
M3^K-;D'X/!QL=;R^45JOP2=72KO@J,^$5Y504]U>T:5OXJSKY#%.(6RRC)O<
M:(G;]QVKC*[0.$$/P-TP- ;F!J='D7\!XF[/_)!\DM">Z53N.5@=+R]F!$%Y
M?D>OPSKA//C<B\'+Z27E<FG:MP-YI[S+WGC^YW K@W\;+D$L+?I0MLU1?^YI
M_77PWL\5:8 _?!V?[?14+-\*YOBM5KI<-'Q/=%[[EZG[?J>*CXI8+LZHR4P9
M&$8@Z%$9D_J/G=27?#O&!=*?/!$Z.1WX#_T'["STCUP5T)B#GKU#MFYDW7YM
ML?BDCL,YYS*OY3+_+;C5V 9<K]SNR#MFFW'M;5>[;J+9^DBW-_W1;ZZ:U4,_
M?P-02P,$%     @ &D"55,PPF=M;!@  OT,  !4   !S<G!T+3(P,C(P-#$Y
M7VQA8BYX;6S-G&UOVS80Q]\7Z'>X>6\VH+)CIQM0HVF1.<D0+$](W&W8,!2R
MQ-C$)-(@Y<3^]B/UT,@Q)5/A:<J+MHIT][_[R[]3:5G.Q\_K.(('(B3E[*@W
M[!_T@+" AY3-CWHKZ?DRH+0',O%9Z$><D:/>ALC>YT]OWWS\SO/@Y.S\"CQ8
M),E2C@>#Q\?'?GA/F>31*E&2LA_P> ">5\1/IE_@]ZS<&&Y)1'Q)(/9E0@3\
MLJ)1.!X=C$8'P^%/_>&HG">(KP4A]!,RAO>#T7"@(V$T?O_S^. 0;B[A-)5A
M,*4Q*:?RY4;0^2*!'X(?(4TZX8R1*"(;.*/,9P'U([@K6GX'YRSHPW$4P:U.
MDZI/2<0#"?NY:D39OV/]UTQW#V_? *C3R&2Z[ZBG3T9^+M8S$?6YF*M>#PX'
M14KO*6.]D_)XF"8,/WSX,$B/EJ,E-<4J\>'@S\N+NV!!8M]3IU^]7$%>1M*Q
M3/=?\" ]A18-0F6$_LDKPCR]RQN.O,-A?RW#WB==,#\[_HQ$%VH+4@]CP2-2
M4U@?3JOW\OADLU3Q9)T0%I)<^9LV#_*HA2#WF:J&+Y64).C/^<,@)%0#,M0;
MGM[0'7ZO?O@ZX8KWXYE,A!\DV_4B?8JX*':F)HYZAJ3!=D,Z[E@$6UJ^" H=
MM;G'?QXQ"+AZW9:)ERH6Z?>"Q\8N\G+<</!K-(N,;6J2U)8>;\*\+W?[O&9"
M96."2+X2"J\F+VWJYU.J#'\7VO]\'#S5?BVMJDN()!=-^W5#\CA6F*L_R5GD
MSVV1?);4$9+FUKGAH N2!B$D)+\I@Y9V!K*%1LM VG;KAN,I2VBRF:@RPH_.
MU05X_1O9V&)9D=P1GO56>$V0"ZXU@DC89A4@+P%I#5!%G %NL?4RR,W[=T/Z
MA <K/3=3U;TMR=LY'0%L;)SO'G/!=5<'B=)"&+2R,YKX;9:)M.P5!\,;(B@/
M3UEXHM[.-.7Q67+'8)JM\)H@#%0-@MC,9B5 U0!=! W?%EHW<FS=/\9BX9;,
MJ5XDL^3*CZV)-N=VNE2H,,*K8]P7"B8]W'7"4P70)9!6"6WT;5@D6#>/ ?(Y
M"[A8<I'>*KE+U.!,^$HM4C83'C;D>H]4IYC;V>36*>Y#8"&/.Q-;!2&M"'E)
MT#61AN1_\&68F9>;PQBB,QJ1JU4\(Z+9Q)3S.AT/@P%N/NX._G,M7,JU.F3R
M2$!C]VN@UZII#%"G_OH\5(LE>D^SF^,OH;92I%.$]UGC%L'N<-<*XY*N2L%V
M+5SN6[5B&((7^,$8B>,P5 9D_L\%9638;!R, IV.0ITEOB?0?00J17'QS_7?
M%1N@*\$UPUK'M&;#@/X+O""B/U&;UV+*']F+P"^GOP;L#79,T#^%H2'_7+(E
MX'49X )T(5S8L0W4H6[G A'S]$W!M;@1_(&RH.%[VRJ-UP!\E3$3]<]BT= W
MZK;$?_;N3J%35,,=@E:LU$U" S^(XW##9>)'?]%E\QL]9H77, IF4Z9!V(I$
M&P.#:DM#D%4"50KSYDU[-NH&P-J+XX-0VJ @?A/@MW.Z>@S*U#C?/>;T$-2.
M#A*XZ?_S6AF'4_P^MQZ LFS6#43]9&)TL^"LX4W#W;R.@*PTP,W'7< T:R'!
MF8I#JHYU\Z2=?LN0-FG:#=0_!$T2PB8\CE<LORDC;6FM2.X(V7HKO";(!=X:
M022"\PJP7<*9XA8;+Z/<M'LWG.]X1 .:4#:_5"MN0?W(EF539D<@UYC@51$N
M"%>I(?'[) ^%OC.\;;5<)K=1WV[8W@BBYX,H+-+'P?17!,3U_;W]PJ%.H2.,
M+4SQ?9$N6.]31<);E8%R'<@*05K)&?2V392!?Z$35/3/I5P1X3X !IW7,0;5
M!LW#L!./.!(5VFT-1E:NU?EHR5'ME#2RY;B\(<%*K:<VP]%L2I/(^A[';EY7
M2YLJ ]Q\W&E98]3"6M3DXJ#4(95W7].TTN_6BJ9!TVZ@3H6OOW![MXEGW'H)
M_BRI(T3-K7/#01<X#4)(9.;*D$D[4]E"HV4D;;O%N6Z>KH.%<DN:/-%MSNWX
M^FDTPJMC,*ZCNWK8U]*B LX3W>WU;;RF6C:/\?G>:4S$7$W-KX(_)@NU&%GZ
MK.&W&2LD.OV$K]X6WQOJ_AE?C2P2Z_D'8T4AR"I!7@KI,[X6;1@^Y+/U4MYQ
MH;;T[YW(=]'LMR^H/?\!4$L#!!0    ( !I E51\<7VBNP0  ),J   5
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ME>8.&^R]E.LC]LG>&8@M?P-02P$"% ,4    "  :0)54>^PCU'$8  !&BP
M#@              @ $     9#,R.34T,&0X:RYH=&U02P$"% ,4    "  :
M0)54@8 !8Q\;   5K   $0              @ &=&   9#,R.34T,&1E>#$P
M,2YH=&U02P$"% ,4    "  :0)54/5637$<#  !T"P  $0
M@ 'K,P  <W)P="TR,#(R,#0Q.2YX<V102P$"% ,4    "  :0)54S#"9VUL&
M  "_0P  %0              @ %A-P  <W)P="TR,#(R,#0Q.5]L86(N>&UL
M4$L! A0#%     @ &D"55'QQ?:*[!   DRH  !4              ( ![ST
L '-R<'0M,C R,C T,3E?<')E+GAM;%!+!08     !0 % $ !  #=0@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
